Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels
NCT02900183
·
clinicaltrials.gov ↗
PHASE2
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class
Stopped
Company decision to not initiate trial
Conditions
Alpha-1 Antitrypsin Deficiency
Interventions
DRUG:
ARC-AAT Injection
Sponsor
Arrowhead Pharmaceuticals